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Abstract The c-fos proto-oncogene was discovered by homol-
ogy to transforming viral genes, leading to speculation that 
transforming viruses had captured a cellular gene involved in cell 
cycle control. Indeed overexpression of c-Fos protein led to 
deregulated growth control, and c-Fos was thought to be so 
critically involved in cell cycle control that transcriptional 
transrepression of its own promoter was interpreted as a negative 
feedback mechanism. However, recent findings render this 
conclusion improbable, Fos transrepression being most parsimo-
niously explained as transcriptional squelching imposed by 
artificially elevated levels of exogenous Fos protein. 
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The gene encoding c-Fos protein, a component of the AP-1 
transcription factor, is induced rapidly and transiently, char-
acterised by pronounced post-inductional transcriptional at-
tenuation (reviewed in [1]). When exogenous c-Fos is over-
expressed the c-fos gene is also transcriptionally repressed. 
This transrepression involves the c-fos promoter serum re-
sponse element (SRE), and the C-terminal domain of c-Fos 
(absent from viral v-Fos) [2-10], which requires serine phos-
phorylation [8,11]. After stimulating v-Fos overexpression 
from a c-fos promoter in transient transfections, there is in-
duction but no post-inductional attenuation of either the ex-
ogenous or endogenous c-fos promoters, and this phenotype is 
dominant when v-Fos and c-Fos are exogenously coexpressed 
[3]· 
The above observations led to the concept that c-Fos reg-
ulates post-inductional transcriptional attenuation of its own 
gene. However, an accumulation of circumstantial evidence 
from different laboratories during the last 2 years make this 
seem unlikely. Transcription from a mutant c-fos alíele, with 
an intact promoter driving the transcription of an mRNA 
encoding a disrupted protein, was induced and down-regu-
lated normally in ES cells and 3T3-like fibrobalsts lacking c-
Fos protein [12], demonstrating that c-Fos is unnecessary for 
post-inductional transcriptional attenuation in these cells. 
However, other molecules may have compensated for this 
function, such as the related Fra-1 protein which transre-
presses similarly to c-Fos [6], and was present in these cells 
[12]. In other work, transcription from the c-fos promoter was 
found to correlate with the activity of inducible kinases tar-
geting the SRE [13]. Their activity is in turn attenuated by 
phosphatases (see references in [14]), without apparent in-
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volvement of c-Fos or Fra-1 proteins, although this cannot 
be excluded. 
An alternative explanation for c-Fos transrepression is 
squelching (Fig. 1), where the c-Fos C-terminal domain would 
sequester a limiting coactivator required for SRE-dependent 
transcription [15]. Several recent developments support this 
concept. For instance, steroid receptors require the transcrip-
tional coactivator CREB binding protein (CBP) to activate 
target genes [16-18] (reviewed in [19]). Inhibition of AP-1 
activity by steroid receptors is caused by receptors sequester-
ing limiting amounts of CBP required by AP-1 [17]. The c-Fos 
transrepressing C-terminal domain also interacts with CBP 
[20], as do the c-fos SRE-transactivating ternary complex fac-
tors (TCF) Sap-la and Elk-1 [21,22]. Whereas expression of 
high amounts of exogenous c-Fos inhibited transactivation 
[23,24], probably by sequestering limiting amounts of CBP 
in the cell (see [19]), the c-Fos C-terminus could activate tran-
scription from a GAL4 binding site when expressed at low 
concentrations and fused to an autonomous GAL4 DNA 
binding domain [20]. Taking these observations together, the 
most likely explanation for c-Fos transrepression of its own 
promoter is transcriptional squelching of the c-fos SRE fol-
lowing transient transfection (Fig. 1). Exogenously overex-
pressed c-Fos would sequester CBP or other coactivators 
away from the c-fos promoter [15], possibly including 
TFIIF-mediated transactivation of the SRE [25-27]. Although 
squelching could potentially contribute to some promoter 
down-modulation after induction of endogenous c-Fos, this 
seems unlikely as judged by the normal post-inductional re-
pression of cells lacking c-Fos [12]. 
The dominant phenotype of v-Fos over transrepression re-
ferred to above needs to be reconciled with this model. Those 
observations were made in studies employing synthetic pro-
moter constructs [3] which unintentionally all contained an 
AP-1-like site in the c-fos promoter [28]. The fact that v-Fos 
expression led to sustained c-fos transcription could therefore 
be due to v-Fos directly binding and transactivating an AP-1 
site in the c-fos or another promoter, which would be mechan-
istically distinct from c-Fos transrepression caused by squelch-
ing. If so, v-Fos could be dominant over c-Fos since CBP 
availability would not affect the activating function of v-
Fos, which lacks the amino acids required for interaction 
with CBP [20]. This explanation provides an experimentally 
testable paradigm. The dominant phenotype of v-Fos should 
require the DNA binding function, unlike transrepression by 
c-Fos. 
Although aberrant Fos levels influence cell transformation, 
there is no compelling evidence that normally regulated c-Fos 
plays any direct role in cell-cycle control [14,29]. Intriguingly, 
unregulated Fos expression perturbs growth control in a man-
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Fig. 1. SRE-transrepression by the c-Fos C-terminal domain, here 
represented as a fusion protein with the DNA-binding domain of 
GAL4 (GAL4-Fos [20]), by squelching. Transcriptional activity of 
GAL4 or SRE promoter elements are depicted as a function of 
GAL4-Fos concentration in cartoon form above, and as dose-re-
sponse curves below. A: In the absence of GAL4-Fos, GAL4-de-
pendent promoters are silent and SRE activity is determined by 
coactivator availability (Co) to SRE-bound transcription factors 
SRF and TCF. B: In the presence of GAL4-Fos, competition for 
coactivator causes some squelching of SREs. However, coactivator 
recruitment to GAL4 sites causes activation relative to 'Α'. C: 
Upon expression of GAL4-Fos in large stoichiometric excess, coacti-
vator is sequestered away from all promoters, severely squelching 
transcription. Since cellular levels of coactivator can be limiting, 
squelching can panoramically regulate the activity of diverse genes 
via coactivator competition between promoters analogously to 'B' 
and ' C above, relative transcriptional activity being dependent on 
affinity for coactivators (for references and more details see 
[15,19,22]). 
ner dependent on the durat ion of expression, bu t not the stage 
of the cell cycle where Fos expression begins [29]. Therefore 
the concept that c-fos is a regulator of the cell cycle which 
orchestrates its own repression by negative feedback has no t 
been strengthened by recent findings. 
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